RecruitingPhase 3NCT06363994

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

Studying Mantle cell lymphoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: InnoCare Pharma Inc.
Intervention: Orelabrutinib(drug)
Enrollment: 476 target
Eligibility: 60 years · All sexes
Timeline: 2024 – 2032

Study locations (30)

Beijing Cancer Hospital, Beijing, China
Peking University Third Hospital, Beijing, China
The First Affiliated Hospital of Bengbu Medical University, Bengbu, China
First Hospital of Jilin University, Changchun, China
Hunan Cancer Hospital, Changsha, China
The First People's Hospital of Changzhou, Changzhou, China
Sichuan Provincial People's Hospital, Chengdu, China
West China Hospital of Sichuan University, Chengdu, China
Chongqinq Cancer Hospital, Chongqing, China
The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
The second Hospital of Dalian Medical University, Dalian, China
Fujing Cancer Hospital, Fuzhou, China
Union Hospital Affiliated to Fujian Medical University, Fuzhou, China
Guangdong Provincial People's Hospital, Guangzhou, China
Sun Yat-sen University Cancer Center, Guangzhou, China
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06363994 on ClinicalTrials.gov

Other trials for Mantle cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Mantle cell lymphoma →

← Back to all trials